53 citations
,
June 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study observed that abnormal hormone levels were associated with lower disease activity in frontal fibrosing alopecia, while thyroid disorders were a common comorbidity among the affected population.
45 citations
,
April 2019 in “International Immunology” This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.
37 citations
,
April 2019 in “Journal of The American Academy of Dermatology” This review assessed the effectiveness of various treatments for frontal fibrosing alopecia and found that intralesional steroids and 5α-reductase inhibitors showed the most positive outcomes in slowing or halting hair loss, though the lack of placebo-controlled studies and consistent outcome measures limits definitive conclusions.
14 citations
,
April 2019 in “International Journal of Women's Health” This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.
101 citations
,
March 2019 in “Cell Stem Cell” This study found that Oncostatin M, via JAK-STAT5 signaling, keeps hair follicle stem cells inactive, and its removal leads to hair growth initiation in mice.
115 citations
,
March 2019 in “Nature Communications” This study identified significant genetic associations with frontal fibrosing alopecia at four genomic loci, suggesting it is a genetically predisposed immuno-inflammatory disorder influenced by the HLA-B*07: 02 allele.
61 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.
66 citations
,
December 2018 in “Dermatology” This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.
23 citations
,
October 2018 in “Australasian Journal of Dermatology” This review highlights that frontal fibrosing alopecia’s increasing incidence may involve immune, genetic, hormonal, and environmental factors, yet its pathogenesis remains complex and not fully understood.
46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
79 citations
,
September 2018 in “Dermatologic therapy” This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
80 citations
,
April 2018 in “Trends in Molecular Medicine” This review discusses the roles of interferon-γ and PPAR-γ-mediated signalling in scarring alopecia, suggesting these pathways as potential therapeutic targets, but it reports no new empirical results.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
13 citations
,
January 2018 in “International Journal of Trichology” In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.
25 citations
,
December 2017 in “Facial Plastic Surgery” This study observed that combining high-potency steroids with pimecrolimus might effectively stabilize hairline recession in frontal fibrosing alopecia patients.
102 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.
36 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.
71 citations
,
October 2017 in “Journal of Investigative Dermatology” PPAR-γ agonists like pioglitazone may help manage lichen planopilaris but don't fully reverse scarring.
22 citations
,
July 2017 in “Australasian journal of dermatology” This study reported that two Chinese patients with lichen planopilaris or frontal fibrosing alopecia experienced satisfactory hair regrowth for 3-4 years following follicular unit extraction hair transplantation after their conditions were stabilized with therapy.
74 citations
,
April 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study classified frontal fibrosing alopecia patients into three clinical patterns, finding that pattern III had the best prognosis and pattern II the worst after treatment with dutasteride and corticosteroids.
12 citations
,
April 2017 in “Experimental and Therapeutic Medicine” This study found that patients with active severe alopecia areata exhibited decreased CD200 expression on T and B lymphocytes, which may be linked to an imbalance in Th1/Th2 immune equilibrium.
95 citations
,
November 2016 in “Journal of The American Academy of Dermatology” This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
68 citations
,
May 2016 in “Experimental dermatology” This review discusses what is known about the pathobiology of frontal fibrosing alopecia and reports no new clinical findings, highlighting potential environmental and genetic factors in disease pathogenesis.
70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
10 citations
,
March 2016 in “Journal of The American Academy of Dermatology” This correspondence critiques a previous report advocating finasteride for frontal fibrosing alopecia, arguing that the evidence on its safety and effectiveness is inconclusive, particularly due to methodological limitations.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.
62 citations
,
June 2015 in “The Journal of Dermatology” This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.
15 citations
,
January 2015 in “Skin Appendage Disorders” This report discusses a series of patients with frontal fibrosing alopecia experiencing increased scalp sweating, which the authors hypothesize may be related to local skin inflammation affecting sweat gland activity.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
339 citations
,
February 2014 in “Journal of The American Academy of Dermatology” This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.
79 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.
220 citations
,
June 2013 in “The Journal of Pathology” This study found that immune privilege collapse in the hair follicle bulge and associated immune responses may contribute significantly to the pathogenesis of lichen planopilaris, suggesting a potential autoimmune basis for the disease.
45 citations
,
April 2013 in “Dermatologic surgery” Hair transplantation might work for some people with frontal fibrosing alopecia, but more research is needed.
117 citations
,
March 2013 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
20 citations
,
December 2010 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that selective downregulation of CD200 in the bulge area might contribute to unusual bulge involvement in a subset of alopecia areata cases.
61 citations
,
September 2010 in “Genomics” This study found distinct gene expression profiles in alopecia areata-affected skin, suggesting T-cell mediated immune responses and unique gene profiles between different stages of the disease.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
53 citations
,
May 2010 in “Dermatologic Surgery” This article appears to be a table of contents or navigation page for a journal, not presenting any new findings or research results.
159 citations
,
November 2007 in “American Journal of Pathology” In this study, researchers found that substance P triggered premature catagen development and immune changes in human scalp hair follicles, providing a possible biological link between stress and hair loss conditions like telogen effluvium and alopecia areata.
113 citations
,
May 2007 in “Journal of the American Academy of Dermatology” This study suggests that tetracycline may be more effective for treating lichen planopilaris than previously thought, alongside topical high-potency and intralesional corticosteroids.
126 citations
,
April 2006 in “International Journal of Dermatology” This study found that frontal fibrosing alopecia and lichen planopilaris have similar histopathological features, but FFA exhibits more prominent apoptosis and less inflammation with spared interfollicular epidermis.
179 citations
,
December 2004 in “Journal of The American Academy of Dermatology” This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.
115 citations
,
November 2004 in “Brain Behavior and Immunity” This study found that stress increases the number of peptidergic nerve fibers and mast cell activity in mouse skin, suggesting a significant neuro-immune interaction under stress.
329 citations
,
January 1997 in “Journal of the American Academy of Dermatology” This study reports that progressive frontal fibrosing alopecia, a distinct and gradually stabilizing form of lichen planopilaris affecting elderly women and often involving eyebrow hair loss, lacks effective treatments.
